Earnings summaries and quarterly performance for Cue Biopharma.
Executive leadership at Cue Biopharma.
Board of directors at Cue Biopharma.
Research analysts who have asked questions during Cue Biopharma earnings calls.
RB
Reni Benjamin
Citizens JMP Securities
3 questions for CUE
Also covers: ALLO, BCAB, BGNE +7 more
ET
Edward Tenthoff
Piper Sandler Companies
1 question for CUE
Also covers: ARVN, ARWR, CAPR +14 more
LG
Leland Gershell
Oppenheimer & Co. Inc.
1 question for CUE
Also covers: ARGX, ASND, CAPR +13 more
MR
Maurice Raycroft
Jefferies Financial Group
1 question for CUE
Also covers: ABEO, AFMD, ALNY +14 more
SW
Stephen Willey
Stifel Financial Corp.
1 question for CUE
Also covers: ABCL, CELC, CGEN +10 more
SW
Stephen Willey
Stifel
1 question for CUE
Also covers: ABCL, ABEO, CGEN +7 more
TT
Ted Tenthoff
Piper Sandler & Co.
1 question for CUE
Also covers: ARVN, CLRB, KPTI +1 more
Recent press releases and 8-K filings for CUE.
Cue Biopharma Announces Pricing of $10 Million Public Offering
CUE
- Cue Biopharma, Inc. announced the pricing of an underwritten public offering expected to generate approximately $10 million in aggregate gross proceeds.
- The offering includes 35,714,286 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchase an aggregate of 17,857,143 shares of common stock.
- Each share of common stock (or pre-funded warrant) and accompanying common stock warrant are being sold together at a combined public offering price of $0.28.
- The company has granted the underwriters an option for 30 days to purchase up to an additional 5,357,140 shares of common stock and/or warrants to purchase up to 2,678,570 shares of common stock.
- The estimated net proceeds from the offering are approximately $8.9 million, or approximately $10.3 million if the underwriters fully exercise their option, which, combined with existing cash and $10 million from a collaboration, are expected to fund operations into the first quarter of 2027.
Dec 19, 2025, 9:22 PM
Cue Biopharma Announces Pricing of Public Offering
CUE
- Cue Biopharma (CUE) announced the pricing of an underwritten public offering for 35,714,286 shares of common stock (or pre-funded warrants) and accompanying common stock warrants to purchase 17,857,143 shares.
- The combined public offering price is $0.28 per share (or $0.279 for pre-funded warrants), expected to generate approximately $10 million in gross proceeds before deductions.
- Each common stock warrant will have an exercise price of $0.30 per share and will expire five years from the date of issuance.
- The offering is anticipated to close on or about December 22, 2025.
Dec 19, 2025, 1:00 PM
Cue Biopharma Announces Proposed Public Offering
CUE
- Cue Biopharma is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants) and accompanying warrants to purchase common stock.
- The company intends to grant the underwriters an option for 30 days to purchase up to an additional 15% of the shares and/or warrants offered.
- The proposed offering is subject to market and other conditions, and there is no assurance regarding its completion, actual size, or terms.
- H.C. Wainwright & Co. is serving as the sole book-running manager, with Newbridge Securities Corporation acting as co-manager for the offering.
Dec 18, 2025, 9:02 PM
Cue Biopharma Reports Q3 2025 Financial Results, Announces ImmunoScape Collaboration, and CEO Appointment
CUE
Earnings
New Projects/Investments
CEO Change
- Cue Biopharma reported collaboration revenue of $2.1 million and a net loss of $7.4 million for the third quarter of 2025, resulting in a net loss per common share of $0.07.
- The company announced a strategic collaboration and license agreement with ImmunoScape, which includes upfront payments totaling $15 million ($10 million in Q4 2025 and $5 million in November 2026) and a 40% equity stake in ImmunoScape.
- Usman Azam, M.D., was appointed President and Chief Executive Officer, effective September 29, 2025, as part of a strategic leadership transition.
- New data from the ongoing Phase 1 trial of CUE-101 showed a complete response and confirmed 50% overall response rate (ORR) in recurrent/metastatic HPV+ head and neck cancer, with 12-month overall survival of 88% and median overall survival (mOS) of 32.7 months.
Nov 12, 2025, 9:00 PM
Cue Biopharma Enters Strategic Collaboration with ImmunoScape for Oncology Programs
CUE
New Projects/Investments
M&A
Revenue Acceleration/Inflection
- On November 6, 2025, Cue Biopharma, Inc. announced a strategic collaboration and license agreement with ImmunoScape Pte. Ltd. for the research, development, and commercialization of its CUE-100 Series in oncology.
- Under the agreement, Cue Biopharma will receive 40% equity in ImmunoScape.
- Cue Biopharma is entitled to $15 million in cash payments, including $5 million received in Q4 2025, $5 million in or prior to December 2025, and an additional $5 million before the first anniversary of the option exercise.
- The company will also receive high single-digit royalties on global net sales and low- to mid-double digit royalties from sublicensing income.
- This collaboration allows Cue Biopharma to focus on its autoimmune disease programs while advancing its Immuno-STAT platform for oncology through ImmunoScape.
Nov 6, 2025, 1:03 PM
Cue Biopharma and ImmunoScape Announce Strategic Collaboration for Solid Tumor Therapy Development
CUE
New Projects/Investments
M&A
- Cue Biopharma and ImmunoScape have entered into an exclusive collaboration and license agreement to advance a novel "Seed-and-Boost" T cell therapy approach for the treatment of solid tumors.
- Under the agreement, Cue Biopharma is entitled to receive an upfront payment totaling $15 million, with $10 million expected in Q4 2025 and $5 million in November 2026.
- Cue Biopharma will also receive a 40% equity stake in ImmunoScape and is eligible for high-single-digit royalty payments on net sales.
- This collaboration allows Cue Biopharma to focus on its autoimmune disease programs while continuing to advance its Immuno-STAT platform for oncology with ImmunoScape.
- IND-enabling studies for this novel immunotherapy approach are on track for 2027 submission.
Nov 6, 2025, 1:00 PM
Cue Biopharma Appoints Usman Azam as New CEO
CUE
CEO Change
Management Change
Executive Compensation
- Cue Biopharma, Inc. announced the appointment of Usman Azam as President and Chief Executive Officer and a member of the Board of Directors, effective September 29, 2025.
- Dr. Azam succeeds Daniel R. Passeri, who retired and resigned from his roles as CEO and Board member, also effective September 29, 2025.
- Dr. Azam's compensation package includes an annual base salary of $620,000, eligibility for a discretionary incentive bonus of up to 50% of his base salary, and stock options to purchase a total of 2,250,000 shares (1,875,000 time-based and 375,000 performance-based).
- In connection with his departure, Mr. Passeri will receive a lump sum cash severance payment of $838,750 and continued COBRA payments for up to 18 months. He will also serve as a strategic advisor until March 30, 2026, and will be granted a stock option to purchase up to 375,000 shares.
Sep 29, 2025, 8:00 PM
Quarterly earnings call transcripts for Cue Biopharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more